Holland Capital

Investment decisions are made by the partnership led by Managing Partners Hubert Verbeek and Ewout Prins. The firm operates with a flat decision-making structure typical of independent Dutch private equity houses, with both partners actively involved in origination, due diligence, and portfolio management. Investment committee approval requires consensus among the senior partners.

Holland Capital typically invests €5 million to €25 million per transaction, using a combination of ordinary equity, preference shares, and shareholder loans. The firm targets majority and minority stakes in companies with revenues of €10 million to €50 million. Its most recent fund, Holland Capital VI, closed at €100 million in 2022 (per the firm, 2022), placing the firm in the lower mid-market segment by European standards.

Deal sourcing relies heavily on Holland Capital's reputation and network within the Dutch accounting, legal, and corporate finance community accumulated since 1981. The firm focuses on proprietary and limited-auction processes, often acting as the first institutional investor in family-owned businesses seeking succession solutions. Sector specialization in healthcare and technology further supports its origination capability.

Holland Capital's core geographic mandate covers the Netherlands and the Flemish region of Belgium. The firm has selectively backed portfolio companies with expansion into Germany and the Nordic region, but it does not make platform investments outside the Benelux. This geographic concentration reflects a deliberate choice to maintain proximity-based governance.

Holland Capital occasionally syndicates transactions with other Dutch private equity firms and family offices on larger deals that exceed its fund concentration limits. The firm does not offer a formal co-investment program for limited partners but has co-invested alongside its own funds on an ad hoc basis with long-standing institutional backers. Co-investment terms follow the main fund's economics.

Holland Capital does not invest in real estate, financial services, or commodity-cyclical heavy industries. The firm's mandate explicitly excludes biotech drug discovery and other pre-revenue life-science models, preferring healthcare services and medical-technology companies with established reimbursement and revenue. Pure-play consumer discretionary businesses have also historically been absent from the portfolio.

Holland Capital operates under the supervision of the Dutch Authority for the Financial Markets, the AFM, as a licensed manager of alternative investment funds under the AIFMD regime. The firm's fund structures are typically Dutch limited partnerships which have reported under the Dutch implementation of the AIFMD since 2014. Compliance and risk management functions sit in-house at the Amsterdam headquarters.